Delivery Order SPE2DB22D1103-SPE2DB25FH2L4
- Not listed
- The Defense Logistics Agency awarded a $15,542.80 firm fixed price delivery order to AmerisourceBergen Drug Corp for Zepbound 12.5 mg/0.5 mL pen injections on September 25, 2025, with an ultimate completion date of September 26, 2025. This non-set-aside competitive award is a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. The order will be fulfilled from the company's location...
- The Defense Logistics Agency awarded a $42,647.15 delivery order to AmerisourceBergen Drug Corp on September 22, 2025, for the supply of Zepbound 10 mg/0.5 ml pen injectors. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999 and extending through December 2026. The products will be delivered to AmerisourceBergen's corporate office...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $1,143.87 firm fixed-price delivery order on July 22, 2025, for Zepbound 15 mg/0.5 ml pen injections. This is a competitively awarded, non-set-aside contract with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, and an ultimate completion date of July 23, 2025. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency awarded a $5,103.02 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Zepbound 10 mg/0.5 mL pen injections on September 22, 2025, with completion scheduled for September 23, 2025. This award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999 through December 2026. The contract was competitively awarded with no set-aside designation, and...
- The Defense Logistics Agency awarded a delivery order valued at $11,161.15 to AmerisourceBergen Drug Corp for the supply of Zepbound 2.5 mg/0.5 mL pen injections on August 5, 2025, with completion scheduled for August 6, 2025. This is a firm fixed price delivery order with no set-aside designation, awarded competitively through an open procurement process. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate...
- The Defense Logistics Agency awarded a $9,847.98 firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 21, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pen injections. The contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. The delivery order is non-competitive and carries an ultimate completion date of...
- The Defense Logistics Agency awarded a $26,418.80 delivery order to AmerisourceBergen Drug Corp for Zepbound 12.5 mg/0.5 mL pen injections on August 7, 2025, with an ultimate completion date of August 8, 2025. This firm fixed-price, non-set-aside contract represents a single delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The place of performance is...
- The Defense Logistics Agency awarded a $3,279.48 delivery order to AmerisourceBergen Drug Corp on September 19, 2025, for the supply of Zepbound 12.5 mg/0.5 ml pen injections. This contract is a firm fixed price delivery order with an ultimate completion date of September 22, 2025, with performance to be conducted at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The award was made through open competition with no set-aside designation, leveraging the company's established...
- The Defense Logistics Agency awarded a delivery order valued at $22,447.88 to AmerisourceBergen Drug Corp on September 2, 2025, for the supply of Zepbound 5 mg/0.5 mL pen injections. This is a firm fixed price delivery order with no set-aside designation, competitively awarded under open competition. The product will be delivered to the contractor's facility in Conshohocken, Pennsylvania, with an ultimate completion date of September 3, 2025. This delivery order represents a single transaction...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency on September 25, 2025, for the supply of Zepbound 12.5 mg/0.5 mL pen injections. The contract carries a ceiling value of $14,492.64 and is structured as a firm fixed price delivery order with an ultimate completion date of September 26, 2025. This award was competitively awarded with no set-aside designation and represents a...
- SPE2DB22D1103Indefinite Delivery Contract
- SPE2DB22D1103-SPE2DB25FH2L4Delivery Order
The Defense Logistics Agency awarded a $1,103.10 delivery order to AmerisourceBergen Drug Corp for Zepbound 12.5 mg/0.5 mL pen injections on September 16, 2025, with a completion date of September 17, 2025. This competitively awarded, firm fixed-price contract has no set-aside designation and is performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. AmerisourceBergen Drug Corp serves as a prime pharmaceutical distributor for federal medical procurement, particularly supporting military and veteran healthcare systems through the DLA Medical Supply Chain. The IDC vehicle enables the company to supply a comprehensive range of pharmaceutical products and medical supplies to customers including the Defense Health Agency and U.S. Coast Guard. Zepbound (tirzepatide), a diabetes and weight management medication, aligns with AmerisourceBergen's extensive portfolio of specialty pharmaceuticals delivered through competitively awarded contracts with the DLA across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.1k | 9/16/25 |